Diabetes Partnership Trifecta Is a Win for European Patients

Abbott and two partners want to bring a new integrated automated insulin delivery system to European countries.

Amanda Pedersen

April 27, 2022

2 Min Read
Double exposure image of a group of business people holding colorful gears to represent team work, partnership, and
Image courtesy of Federico Caputo / Alamy Stock Photo

In a diabetes tech trifecta, Abbott has partnered with CamDiab and Ypsomed to develop an integrated automated insulin delivery system. The partnership's initial focus is on European countries.

The new integrated automated insulin delivery system is being designed to connect Abbott's FreeStyle Libre 3 continuous glucose monitoring sensor to CamDiab's CamAPS FX mobile app, which connects with Ypsomed's mylife YpsoPump – creating a smart, automated process to deliver insulin based on real-time glucose data. The connected, smart wearable solution is designed to continuously monitor a person’s glucose levels and automatically adjust and deliver the right amount of insulin at the right time, removing the guesswork of insulin dosing.

The companies intend to complete development of the new system by the end of the year, with commercial availability expected thereafter.

Diabetes management devices shown in an infographic

"Our goal is to make diabetes care as easy as possible, which is why Abbott continues to expand its team of insulin delivery partners, digital coaching, and technology leaders," said Jared Watkin, senior vice president of Abbott’s diabetes care business. "We want to deliver new advanced solutions that simplify and make it possible for people to spend less time thinking about diabetes and more time living."

Abbott's FreeStyle Libre 3 is a 2022 Medical Design Excellence Awards winner.

"Poor glucose control leads to an increased risk of diabetes complications such as blindness, and heart and kidney disease. We want to help people with diabetes better manage their glucose through advanced technology. Our CamAPS FX, already approved in Europe, is a highly adaptive algorithm that when integrated with Abbott’s sensor is being designed to communicate with Ypsomed’s insulin pump to provide the optimal insulin dose, lifting the burden of managing a condition that is relentlessly unpredictable day and night," said Roman Hovorka, director of CamDiab.

The news represents the power of collaboration in medtech.

"We are convinced that major challenges of society can only be addressed through partnerships. We are therefore proud to expand our partners and connectivity to offer more freedom of choice in managing diabetes," said Ypsomed CEO Simon Michel.

When combined, the mylife YpsoPump with the FreeStyle Libre 3 sensor and CamAPS FX app will create a compact and lightweight automated insulin delivery system that is discreet and simple to use, Michel said.

About the Author(s)

Amanda Pedersen

Amanda Pedersen is a veteran journalist and award-winning columnist with a passion for helping medical device professionals connect the dots between the medtech news of the day and the bigger picture. She has been covering the medtech industry since 2006.

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like